Precisely Tuned Inhibition of HIF Prolyl Hydroxylases Is Key for Cardioprotection After Ischemia
暂无分享，去创建一个
P. Ratcliffe | M. Coleman | D. Biggs | B. Davies | C. Pugh | Atsushi Yamamoto | D. Katschinski | A. Zieseniss | A. Jatho | Ana M Vergel Leon | Katja Brechtel-Curth
[1] P. Ratcliffe,et al. Systemic silencing of Phd2 causes reversible immune regulatory dysfunction , 2019, The Journal of clinical investigation.
[2] J. Fandrey,et al. Things get broken: the hypoxia-inducible factor prolyl hydroxylases in ischemic heart disease , 2019, Basic Research in Cardiology.
[3] P. Ratcliffe,et al. Pharmacological targeting of the HIF hydroxylases--A new field in medicine development. , 2016, Molecular aspects of medicine.
[4] P. Ratcliffe,et al. HIF hydroxylase pathways in cardiovascular physiology and medicine. , 2015, Circulation research.
[5] Peter Libby,et al. Cardiovascular remodelling in coronary artery disease and heart failure , 2014, The Lancet.